Germany's Merck and GlaxoSmithKline have announced a global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult to treat cancers, in a deal worth up to 3.7 billion euros.Original Article
You may also like
Exploring 3D Printing for Solid Dosage Drugs
Control Strategies and Method Development for...
CPHI Milan 2024: Fill/Finish and Sustainability
CPHI Milan 2024: Industry Trends Impacting Oral Solid...
CPHI Milan 2024: Evolution of Coating Design
Colorcon and LOTTE Fine Chemical Announce Partnership
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.